54 results about "Histone methylation" patented technology

The methods and compositions described herein relate to producing, expanding, enriching, and / or maintaining hematopoietic stem cells ex vivo by treating the cells with an agent(s) that exhibits two or more activities selected from modulation of histone methylation; inhibition of TGFβ signaling; inhibition of p38 signaling; activation of canonical Wnt signaling; and modulation of histone acetylation. In some embodiments, the technology described herein relates to transplantation of hematopoietic stem cells.

A pharmaceutical composition for induction therapy which has a hypomethylating agent and a histone deacetylase inhibitor (“HDAC inhibitor”); wherein the hypomethylating agent is a DNA and histone methylation inhibitor such as cladribine and the HDAC inhibitor is, for example, entinostat, panobinostat, vorinostat, and / or romedepsin; further wherein the hypomethylating agent and the HDAC inhibitor are combined in formulations for various administrations including e.g., a continuous delivery system such as a transdermal patch of at least one reservoir or a plurality of reservoirs, oral, a fixed-dose oral combination, intravenous, and combinations thereof. This pharmaceutical composition for induction therapy is used with a monoclonal antibody in the treatment of various cancers, sarcomas, and other malignancies.

Disclosed are methods and kits for genome-wide methylation of GpC sites and for genome-wide chromatin structural determination. Specifically, the methods and kits of the present invention make possible the simultaneous determination of endogenous DNA methylation state and chromatin architecture across the entire genome.

A population of enteroendocrine cells (EEC) is obtained from a mammalian post-natal cell population, such as a population including post-natal stem cells, by treating the population with a plurality of small molecules that upregulate ChgA and promote differentiation of the cells to form the enteroendocrine cells. The upregulation of ChgA is such that the fraction of cells expressing CGA in the obtained cell population, as measured by a ChgA Immunostaining Assay, is at least about 1.5%. Small molecules that can be used to differentiate the post-natal cells into the enteroendocrine cells can include at least one of a Wnt activator, a Notch inhibitor, a Wnt inhibitor, a MEK / ERK inhibitor, a growth factor, a HDAC inhibitor, a Histone Methylation Inhibitor, a Tgf-β inhibitor, and a NeuroD1 activator. Also, the insulin expression of a population of mammalian cells is increased by treating the population with a plurality of small molecules that increase the insulin expression.

Medulloblastoma (MB) is the most common malignant brain tumor of children. To identify the genetic alterations in this tumor type, we searched for copy number alterations using high density microarrays and sequenced all known protein-coding genes and miRNA genes using Sanger sequencing. We found that, on average, each tumor had 11 gene alterations, markedly fewer than in common adult cancers. In addition to alterations in the Hedgehog and Wnt pathways, our analysis led to the discovery of genes not previously known to be altered in MBs. Most notably, inactivating mutations of the histone H3K4 trimethylase genes MLL2 or MLL3 were identified in 16% of MB patients. These results demonstrate key differences between the genetic landscapes of adult and childhood cancers, highlight dysregulation of developmental pathways as an important mechanism underlying MBs, and identify a role for a specific type of histone methylation in human tumorigenesis.

The invention discloses an application of histone methylation H3K4me3 in pig ovary granulosa cells, and belongs to the technical fields of cell engineering and genetic engineering. The invention takes H3K4me3 as an entry point, and uses cell biology methods to study its influence on the function of porcine ovary granulosa cells. The technical scheme of the invention is carefully designed and the result is reliable. In order to confirm the influence of H3K4me3 on the function of porcine ovary granulosa cells, the present invention verifies from multi-level and multi-angle, at cell level and protein level. The present invention clarifies the influence of H3K4me3 on the function of porcine ovarian granulosa cells: H3K4me3 can promote the proliferation of porcine ovarian granulosa cells, inhibit the apoptosis of porcine ovarian granulosa cells, and reduce the proportion of porcine ovarian granulosa cells blocked in the GO / G1 phase; It is of great application value to study the mechanism of histone methylation on the development of ovarian follicles and the reproductive performance of sows.

The invention discloses a histone methylating transferase and coded gene and application, which contains protein (a) or protein (b), wherein the (a) is composed of residue sequence of amino acid in the sequence list 1; (b) protein is composed of (a) derivatized plant in the sequence list 1; the transferase controls the swivelling activity of Tos17, which makes Tos17 insert new location to produce mutant.